Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Prior treatment

• Previous participation in this study. Participation is defined as signed informed consent.
• Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before the screening visit, except Coronavirus Disease 2019 (COVID-19) related trials (this is allowed).
• Treatment with any glucagon-like peptide-1 receptor agonists (GLP-1 RA) medication prior to the screening visit.
• Myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening.
• Use of systemic immunosuppressive treatment within 90 days prior to screening.
• Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of ≤ 14 days.
• Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 12 months prior to screening.

Other illness

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma.
• History of pancreatitis (acute or chronic).
• Participants presently classified as being in New York Heart Association (NYHA) Class IV heart failure.
• History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).

Lab values

• Renal impairment defined as estimated glomerular filtration rate (eGFR) below 30 milliliters/minute (mL/min)/1.73 meter square (m\^2) as per MDRD-4 (Modification of Diet in Renal Disease).
• Participants with alanine aminotransferase (ALT) \> 2.5 x upper normal limit (UNL).

Other

• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
• Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
• Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episodes as judged by the investigator.

• Participants diagnosed (clinically) with type 2 diabetes greater than equal to (≥) 90 days prior to the screening visit.
• Stable daily dose of Oral Antidiabetic Drug (OAD) and/or insulin treatment for ≥ 60 days prior to the screening visit.
• HbA1c 7.5-10% (59-86 millimoles per mole \[mmol/mol\]) (both inclusive) in Visit 1.
• Participants in which Ozempic is indicated according to approved local label.
• Fundoscopy/Fundus photography record less than equal to (≤) 12 months.